These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 26297257

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
    Michelotti G, Jiang X, Sosa JA, Diehl AM, Henderson BB.
    Oncotarget; 2015 Oct 27; 6(33):34549-60. PubMed ID: 26416247
    [Abstract] [Full Text] [Related]

  • 3. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C, Guo Y, Lv Y, Nanding A, Shi T, Qin H, He J.
    PLoS One; 2016 Oct 27; 11(12):e0167414. PubMed ID: 27936049
    [Abstract] [Full Text] [Related]

  • 4. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A, Boskovic S, Paunovic I, Bozic V, Cvejic D.
    APMIS; 2016 Apr 27; 124(4):271-7. PubMed ID: 26750533
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 27; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 6. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.
    Exp Clin Endocrinol Diabetes; 2014 May 27; 122(5):268-72. PubMed ID: 24839220
    [Abstract] [Full Text] [Related]

  • 7. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J, Yang Y, Zhao J, Shi L, Xu Y, Yu K, Guo C.
    Pathol Res Pract; 2019 Apr 27; 215(4):761-765. PubMed ID: 30819583
    [Abstract] [Full Text] [Related]

  • 8. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C, Qin H, Ding C, Sun Y, Lyu Y, Shi T.
    Zhonghua Zhong Liu Za Zhi; 2015 Feb 27; 37(2):123-7. PubMed ID: 25975689
    [Abstract] [Full Text] [Related]

  • 9. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S, Šelemetjev S, Đorić I, Rončević J, Janković Miljuš J, Živaljević V, Išić Denčić T.
    Eur J Surg Oncol; 2020 Oct 27; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [Abstract] [Full Text] [Related]

  • 10. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
    Park VY, Kim EK, Moon HJ, Yoon JH, Kwak JY.
    Medicine (Baltimore); 2016 Jul 27; 95(29):e4292. PubMed ID: 27442672
    [Abstract] [Full Text] [Related]

  • 11. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B.
    PLoS One; 2015 Jul 27; 10(7):e0132821. PubMed ID: 26177218
    [Abstract] [Full Text] [Related]

  • 12. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F, Gnemmi V, Devos P, Aubert S, Crépin M, Coppin L, Ramdane N, Bouchindhomme B, d'Herbomez M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wémeau JL, Leteurtre E.
    Thyroid; 2014 Sep 27; 24(9):1375-84. PubMed ID: 25012490
    [Abstract] [Full Text] [Related]

  • 13. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
    Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, Accardo G, Sacco V, Bellastella A, Pannone G.
    Thyroid; 2011 Apr 27; 21(4):391-9. PubMed ID: 21385081
    [Abstract] [Full Text] [Related]

  • 14. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
    Li W, Ming H, Sun D, Li W, Wang D, Zhang G, Tan J.
    Pathol Res Pract; 2017 Mar 27; 213(3):183-188. PubMed ID: 28214213
    [Abstract] [Full Text] [Related]

  • 15. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR, Boschin IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F, Mian C.
    Clin Chem Lab Med; 2011 Feb 27; 49(2):325-9. PubMed ID: 21175381
    [Abstract] [Full Text] [Related]

  • 16. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
    Campennì A, Ruggeri RM, Giuffrè G, Siracusa M, Alibrandi A, Cardile D, La Torre F, Lanzafame H, Giacoppo G, Ieni A, Trimarchi F, Tuccari G, Baldari S.
    Nucl Med Commun; 2021 Jun 01; 42(6):611-618. PubMed ID: 33625185
    [Abstract] [Full Text] [Related]

  • 17. BRAFV600E Immunohistochemistry in Papillary Thyroid Carcinomas: Relationship Between Clinical and Morphological Parameters.
    Kombak FE, Özkan N, Uğurlu MÜ, Kaya H.
    Turk Patoloji Derg; 2019 Jun 01; 35(2):83-91. PubMed ID: 30632125
    [Abstract] [Full Text] [Related]

  • 18. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
    Chai YJ, Yi JW, Jee HG, Kim YA, Kim JH, Xing M, Lee KE.
    PLoS One; 2016 Jun 01; 11(7):e0159235. PubMed ID: 27410688
    [Abstract] [Full Text] [Related]

  • 19. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.
    Shao H, Yu X, Wang C, Wang Q, Guan H.
    Endocrine; 2014 Jun 01; 46(2):285-91. PubMed ID: 24272599
    [Abstract] [Full Text] [Related]

  • 20. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA.
    JAMA Otolaryngol Head Neck Surg; 2013 Nov 01; 139(11):1164-70. PubMed ID: 24030686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.